DEF: Day One Biopharmaceuticals Announces 2025 Annual Meeting of Stockholders

Day One Biopharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 2, 2025, to elect directors, ratify the appointment of its accounting firm, and vote on executive compensation.

Summary

• Day One Biopharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 2, 2025.
• Stockholders will vote to elect two Class I directors for three-year terms, ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approve, on a non-binding advisory basis, the compensation of the company's named executive officers.
• The record date for determining stockholders eligible to vote at the meeting is April 7, 2025.
• The board of directors recommends voting for the election of the director nominees, for the ratification of PricewaterhouseCoopers LLP, and for the approval of the compensation of the named executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions, and the company expresses confidence in its governance and compensation practices.

Positives

• The company is committed to good corporate governance practices.
• The board of directors is composed of a majority of independent directors.
• The company has comprehensive risk oversight practices, including cybersecurity and data privacy.
• The company has adopted a Code of Business Conduct and Ethics that applies to all directors, officers, employees, consultants and contractors.
• The company believes that corporate social responsibility initiatives are important to its business and to creating sustainable value for its stockholders and wider stakeholder group.

Risks

• The proxy statement includes forward-looking statements that are subject to risks, assumptions, estimates, and uncertainties.
• Cybersecurity risks are a concern, and the company has adopted controls on data security and a procedure for data incident detection, containment, response, and remediation.

Future Outlook

The proxy statement includes forward-looking statements regarding future operating results, financial condition, business strategy, market growth, and objectives for future operations, which are subject to risks and uncertainties.

Management Comments

• Jeremy Bender, Chief Executive Officer and President: 'Your vote as a Day One Biopharmaceuticals, Inc. stockholder is very important.'
• The board of directors believes that Mr. Nicholsons strategic vision for our business and deep knowledge of our industry make him well qualified to serve as chair of our board of directors.

Industry Context

The document provides insight into the corporate governance practices, executive compensation, and board composition of a biopharmaceutical company, which are common topics in proxy statements within the biotech industry.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes biotechnology companies such as ACADIA Pharmaceuticals, BioCryst Pharmaceuticals, and others, suggesting a focus on companies of similar size, stage, and market capitalization.
• The compensation structure, including base salary, annual bonus, and equity awards, aligns with common practices in the biopharmaceutical industry to attract and retain talent.
• The company's corporate governance practices, such as having a majority independent board and a Code of Business Conduct and Ethics, are consistent with Nasdaq listing requirements and industry best practices.

Related Party Transactions

• In July 2024, AI Day1 LLC purchased Pre-Funded Warrants to purchase up to 827,586 shares of Day One's common stock in a private placement.
• Daniel Becker, who served as Managing Director at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, Inc. and an affiliate of AI Day1 LLC, served as a member of Day One's board of directors from December 2019 through May 23, 2024.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Employees are affected by the company's compensation policies and corporate social responsibility initiatives.
• The company's performance and governance practices can impact its relationships with partners, customers, and the communities in which it operates.

Next Steps

• Stockholders are encouraged to read the proxy statement and vote their shares.
• The company will hold the Annual Meeting on June 2, 2025, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Corporate Governance, Executive Compensation, Director Election, PricewaterhouseCoopers, Audit Committee